Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.

Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators Group.

Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1793. [Epub ahead of print]

PMID:
32243669
2.

Single- and multi-site pacing strategies for optimal cardiac resynchronization therapy: impact on device longevity and therapy cost.

D'Onofrio A, Bertini M, Infusino T, D'Arienzo G, Cipolletta L, Bianchi V, Licciardello G, Savarese G, Russo G, Ricciardi D, Manzo M, Fabbri F, Notarstefano P, Santini L, Campari M, Valsecchi S, Forleo GB.

J Interv Card Electrophysiol. 2020 Mar 17. doi: 10.1007/s10840-020-00711-3. [Epub ahead of print]

PMID:
32185588
3.
4.

Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence.

Stolfo D, Savarese G.

Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1761. [Epub ahead of print] No abstract available.

PMID:
32103601
5.

Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.

Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, Dahlström U, Anker SD, Lainscak M, Hernandez AF, Pitt B, Lund LH.

Eur J Heart Fail. 2020 Feb 20. doi: 10.1002/ejhf.1757. [Epub ahead of print]

PMID:
32078214
6.

Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis.

Stolfo D, Albani S, Savarese G, Barbati G, Ramani F, Gigli M, Biondi F, Dal Ferro M, Zecchin M, Merlo M, Sinagra G.

Int J Cardiol. 2020 Feb 11. pii: S0167-5273(19)34945-9. doi: 10.1016/j.ijcard.2020.02.025. [Epub ahead of print]

PMID:
32067834
7.

Erratum to "Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum" [Int. J. Cardiol. 298 (2019) 59-68].

Savarese G, Jonsson Å, Hallberg AC, Dahlström U, Edner M, Lund LH.

Int J Cardiol. 2020 Jan 20. pii: S0167-5273(20)30194-7. doi: 10.1016/j.ijcard.2020.01.023. [Epub ahead of print] No abstract available.

PMID:
31973886
8.

Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?

Savarese G.

Eur Cardiol. 2019 Dec 18;14(3):139-140. doi: 10.15420/ecr.2019.14.3.GE3. eCollection 2019 Dec. Review. No abstract available.

9.

PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction.

Lund LH, Savarese G.

J Card Fail. 2019 Dec;25(12):1012-1013. doi: 10.1016/j.cardfail.2019.11.017. No abstract available.

PMID:
31818392
10.

Iron deficiency in heart failure.

Lund LH, Savarese G, Dahlström U.

Int J Cardiol. 2020 Jan 15;299:207. doi: 10.1016/j.ijcard.2019.09.051. No abstract available.

PMID:
31791539
11.

Detection of SRY-positive46,XX male syndrome by the analysis of cell-free fetal DNA via non-invasive prenatal testing.

De Falco L, Savarese G, Suero T, Amabile S, Ruggiero R, Savarese P, Fico A.

Clin Case Rep. 2019 Sep 7;7(10):1977-1981. doi: 10.1002/ccr3.2389. eCollection 2019 Oct.

12.

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.

Eur Heart J. 2019 Sep 21;40(36):3010-3012. doi: 10.1093/eurheartj/ehz650. No abstract available.

PMID:
31541549
13.

Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum.

Savarese G, Jonsson Å, Hallberg AC, Dahlström U, Edner M, Lund LH.

Int J Cardiol. 2020 Jan 1;298:59-65. doi: 10.1016/j.ijcard.2019.08.049. Epub 2019 Aug 28. Erratum in: Int J Cardiol. 2020 Jan 20;:.

PMID:
31521440
14.

Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry.

Stolfo D, Uijl A, Benson L, Schrage B, Fudim M, Asselbergs FW, Koudstaal S, Sinagra G, Dahlström U, Rosano G, Savarese G.

Eur J Heart Fail. 2020 Jan;22(1):103-112. doi: 10.1002/ejhf.1615. Epub 2019 Oct 23.

PMID:
31478583
15.

Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.

Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde C, Braunschweig F, Savarese G.

Circulation. 2019 Nov 5;140(19):1530-1539. doi: 10.1161/CIRCULATIONAHA.119.043012. Epub 2019 Sep 3.

PMID:
31476893
16.

Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL.

Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):104-114. doi: 10.1093/ehjcvp/pvz033.

PMID:
31397840
17.

Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.

Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.

Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):86-93. doi: 10.1093/ehjcvp/pvz036.

PMID:
31392312
18.

The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.

Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S.

Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):97-103. doi: 10.1093/ehjcvp/pvz029.

PMID:
31298686
19.

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction.

Löfström U, Hage C, Savarese G, Donal E, Daubert JC, Lund LH, Linde C.

ESC Heart Fail. 2019 Aug;6(4):830-839. doi: 10.1002/ehf2.12458. Epub 2019 Jun 17.

20.

Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction.

Stolfo D, Savarese G.

Card Fail Rev. 2019 May 24;5(2):70-73. doi: 10.15420/cfr.2019.6.2. eCollection 2019 May. Review.

21.

Reply: Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes.

Savarese G, Lund LH, Carrero JJ.

JACC Heart Fail. 2019 Jun;7(6):533-534. doi: 10.1016/j.jchf.2019.03.007. No abstract available.

PMID:
31146879
22.

Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.

Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, Sinagra G, Dahlström U, Savarese G.

JACC Heart Fail. 2019 Jun;7(6):505-515. doi: 10.1016/j.jchf.2019.03.011. Erratum in: JACC Heart Fail. 2020 Apr;8(4):345-346.

PMID:
31146874
23.

Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.

Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators.

Eur J Heart Fail. 2019 Nov;21(11):1383-1397. doi: 10.1002/ejhf.1532. Epub 2019 Jun 18.

PMID:
31132222
24.

Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.

Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A.

Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180. doi: 10.1093/ehjcvp/pvz016.

PMID:
31119266
25.

Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization.

Savarese G, Lund LH, Dahlström U, Strömberg A.

J Am Heart Assoc. 2019 May 21;8(10):e011737. doi: 10.1161/JAHA.118.011737.

26.

N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.

Faxén UL, Lund LH, Orsini N, Strömberg A, Andersson DC, Linde C, Dahlström U, Savarese G.

Int J Cardiol. 2019 Jul 15;287:66-72. doi: 10.1016/j.ijcard.2019.04.023. Epub 2019 Apr 11.

PMID:
31005415
27.

The GUIDE-IT heart failure risk prediction model: another fish in the sea?

Uijl A, Lund LH, Savarese G.

Eur J Heart Fail. 2019 Jun;21(6):779-780. doi: 10.1002/ejhf.1472. Epub 2019 Apr 14. No abstract available.

PMID:
30983078
28.

Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.

Chen X, Savarese G, Dahlström U, Lund LH, Fu M.

Clin Res Cardiol. 2019 Dec;108(12):1394-1405. doi: 10.1007/s00392-019-01477-z. Epub 2019 Apr 12.

PMID:
30980205
29.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
30.

Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.

Savarese G, Vedin O, D'Amario D, Uijl A, Dahlström U, Rosano G, Lam CSP, Lund LH.

JACC Heart Fail. 2019 Apr;7(4):306-317. doi: 10.1016/j.jchf.2018.11.019. Epub 2019 Mar 6. Erratum in: JACC Heart Fail. 2019 Aug;7(8):735-736.

31.

Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction.

Sartipy U, Savarese G, Dahlström U, Fu M, Lund LH.

Eur J Heart Fail. 2019 Apr;21(4):471-479. doi: 10.1002/ejhf.1389. Epub 2019 Jan 30.

32.

Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.

Savarese G, Xu H, Trevisan M, Dahlström U, Rossignol P, Pitt B, Lund LH, Carrero JJ.

JACC Heart Fail. 2019 Jan;7(1):65-76. doi: 10.1016/j.jchf.2018.10.003. Epub 2018 Dec 12.

PMID:
30553905
33.

Clinical and research implications of serum versus plasma potassium measurements.

Cooper LB, Savarese G, Carrero JJ, Szabo B, Jernberg T, Jonsson Å, Dahlbom C, Dahlström U, Larson A, Lund LH.

Eur J Heart Fail. 2019 Apr;21(4):536-537. doi: 10.1002/ejhf.1371. Epub 2018 Nov 28. No abstract available.

34.
35.

Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?

Galli M, Andreotti F, Savarese G, D'Amario D, Vergallo R, Della Bona R, Calò L, Porto I, Crea F.

Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):55-56. doi: 10.1093/ehjcvp/pvy039. Review. No abstract available.

PMID:
30289484
36.

Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.

Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, Savarese G, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J.

Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):230-236. doi: 10.1093/ehjcvp/pvy028. Review. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):36. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):36.

PMID:
30099530
37.

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure.

Savarese G, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH.

Ups J Med Sci. 2019 Jan;124(1):65-69. doi: 10.1080/03009734.2018.1490831. Epub 2018 Aug 9. Review.

38.

Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury.

Akhmedov A, Bonetti NR, Reiner MF, Spescha RD, Amstalden H, Merlini M, Gaul DS, Diaz-Cañestro C, Briand-Schumacher S, Spescha RS, Semerano A, Giacalone G, Savarese G, Montecucco F, Kulic L, Nitsch RM, Matter CM, Kullak-Ublick GA, Sessa M, Lüscher TF, Beer JH, Liberale L, Camici GG.

J Cereb Blood Flow Metab. 2019 Nov;39(11):2233-2245. doi: 10.1177/0271678X18793266. Epub 2018 Aug 3. Erratum in: J Cereb Blood Flow Metab. 2019 Nov;39(11):NP1.

PMID:
30073881
39.

Sex Differences in Heart Failure.

Savarese G, D'Amario D.

Adv Exp Med Biol. 2018;1065:529-544. doi: 10.1007/978-3-319-77932-4_32. Review.

PMID:
30051405
40.

The Cardiac Rehabilitation Psychodynamic Group Intervention (CR-PGI): An Explorative Study.

Venuleo C, Mangeli G, Mossi P, Amico AF, Cozzolino M, Distante A, Ignone G, Savarese G, Salvatore S.

Front Psychol. 2018 Jun 20;9:976. doi: 10.3389/fpsyg.2018.00976. eCollection 2018.

41.

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.

Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):180-188. doi: 10.1093/ehjcvp/pvy015.

PMID:
29726985
42.

Adherence to 2016 European Society of Cardiology guidelines predicts outcome in a large real-world population of heart failure patients requiring cardiac resynchronization therapy.

Stabile G, Pepi P, Palmisano P, D'Onofrio A, De Simone A, Caico SI, Pecora D, Rapacciuolo A, Arena G, Marini M, Pieragnoli P, Badolati S, Savarese G, Maglia G, Iuliano A, Botto GL, Malacrida M, Bertaglia E.

Heart Rhythm. 2018 Nov;15(11):1675-1682. doi: 10.1016/j.hrthm.2018.04.011. Epub 2018 Apr 14.

PMID:
29665405
43.

Corrigendum to "Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study" [Int. J. Cardiol. 226 (2017) 65-70].

Savarese G, Donal E, Hage C, Oger E, Persson H, Daubert JC, Linde C, Lund LH; KaRen investigators.

Int J Cardiol. 2018 Jun 15;261:240. doi: 10.1016/j.ijcard.2018.03.075. Epub 2018 Mar 27. No abstract available.

PMID:
29602583
44.

Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.

Savarese G, Orsini N, Hage C, Dahlström U, Vedin O, Rosano GMC, Lund LH.

J Card Fail. 2018 Jun;24(6):365-374. doi: 10.1016/j.cardfail.2018.03.010. Epub 2018 Mar 27.

PMID:
29597053
45.

Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.

Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, Lund LH.

Eur J Heart Fail. 2018 Sep;20(9):1326-1334. doi: 10.1002/ejhf.1182. Epub 2018 Mar 26. Review.

46.

Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.

Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlström U, Lund LH.

JACC Heart Fail. 2018 Mar;6(3):246-256. doi: 10.1016/j.jchf.2017.12.014. Epub 2018 Feb 7.

47.

Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.

Savarese G, Sartipy U, Friberg L, Dahlström U, Lund LH.

Heart. 2018 Jul;104(13):1093-1100. doi: 10.1136/heartjnl-2017-312720. Epub 2018 Jan 25.

PMID:
29371374
48.

Is ejection fraction in heart failure a limitation or an opportunity?

Lund LH, Vedin O, Savarese G.

Eur J Heart Fail. 2018 Mar;20(3):431-432. doi: 10.1002/ejhf.1106. Epub 2018 Jan 15. No abstract available.

49.

Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, Savarese G, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS.

Eur Heart J. 2018 Jun 21;39(24):2274-2281. doi: 10.1093/eurheartj/ehx625. No abstract available.

PMID:
29126266
50.

Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue.

Savarese G, Lund LH.

Int J Cardiol. 2017 Dec 15;249:77-78. doi: 10.1016/j.ijcard.2017.09.180. No abstract available.

PMID:
29121762

Supplemental Content

Loading ...
Support Center